Key Democrats Back BIO Industry Against Consumers to Delay Generic Medicines (Biosimilars)
Unlike for pharmaceutical drugs, there is no easy way to get FDA approval for a generic biologic product. Congress is considering an FDA reform to fix this, but it is being derailed by the BIO.
James Love | Posted 05.25.2011